Enrollment Status: Open
The purpose of this study is to evaluate the safety, tolerability, and efficacy of N-803, an IL-15 superagonist, with or without combination broadly neutralizing antibodies (bNAbs), to induce HIV-1 control during analytic treatment interruption (ATI).
This study is looking for people with HIV who are taking HIV treatment and whose viral load is undetectable. The study will see if an experimental product called IL-15 given alone or in combination with two antibodies directed against HIV, called broadly neutralizing antibodies (bNAbs), is safe and leads to control of HIV. Half of the participants will receive 8 doses of IL-15 given every 3 weeks and half will receive 8 doses of IL-15 given every 3 weeks plus the bNAbs. After receiving these products, participants will temporarily stop taking their HIV treatment and will be monitored closely to see if their HIV is controlled without HIV treatment.
Basic Eligibility Criteria: